$GYRE
GYRE THERAPEUTICS, INC.

2019 Form 10-K Financial Statement

#000156459020005546 Filed on February 20, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018 Q1
Revenue $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -96.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.42M $3.450M $2.910M
YoY Change 8.66% 33.2% 22.27%
% of Gross Profit
Research & Development $43.86M $8.240M $3.771M
YoY Change 104.25% 131.46% 82.97%
% of Gross Profit
Depreciation & Amortization $146.0K $0.00 $33.00K
YoY Change -2.01% -100.0% -31.25%
% of Gross Profit
Operating Expenses $57.28M $11.68M $6.685M
YoY Change 166.73% 89.92% 50.5%
Operating Profit -$57.28M -$6.679M
YoY Change 60.13%
Interest Expense $2.145M $690.0K $285.0K
YoY Change -3.77% 762.5% 1576.47%
% of Operating Profit
Other Income/Expense, Net -$39.00K $150.0K $1.468M
YoY Change -102.36% 9075.0%
Pretax Income -$55.18M -$10.84M -$5.040M
YoY Change 83.57% 88.52% 21.74%
Income Tax
% Of Pretax Income
Net Earnings -$55.18M -$10.84M -$5.042M
YoY Change 83.59% 88.52% 21.85%
Net Earnings / Revenue -50420.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.598M -$907.1K -$560.6K
COMMON SHARES
Basic Shares Outstanding 11.89M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 2018 Q4 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.90M $120.1M $143.5M
YoY Change -35.97% 270.68% 889.66%
Cash & Equivalents $15.40M $31.21M $126.6M
Short-Term Investments $61.50M $88.90M $17.00M
Other Short-Term Assets $4.200M $3.900M $1.900M
YoY Change 7.69% -40.91% -86.13%
Inventory
Prepaid Expenses
Receivables $15.00M
Other Receivables $0.00
Total Short-Term Assets $96.10M $124.0M $145.4M
YoY Change -22.5% 217.11% 409.53%
LONG-TERM ASSETS
Property, Plant & Equipment $2.200M $386.0K $300.0K
YoY Change 450.0% 39.86% -24.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $543.0K $100.0K
YoY Change -40.0% 324.22% 0.0%
Total Long-Term Assets $2.500M $929.0K $500.0K
YoY Change 177.78% 124.94% -4.58%
TOTAL ASSETS
Total Short-Term Assets $96.10M $124.0M $145.4M
Total Long-Term Assets $2.500M $929.0K $500.0K
Total Assets $98.60M $124.9M $145.9M
YoY Change -21.06% 216.15% 402.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.300M $1.248M $1.400M
YoY Change 258.33% 67.07% 55.73%
Accrued Expenses $9.600M $3.500M $1.500M
YoY Change 174.29% 29.63% 7.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.90M $4.801M $2.900M
YoY Change 502.08% -45.06% -80.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M $200.0K $100.0K
YoY Change 550.0%
Total Long-Term Liabilities $1.300M $200.0K $100.0K
YoY Change 550.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.90M $4.801M $2.900M
Total Long-Term Liabilities $1.300M $200.0K $100.0K
Total Liabilities $30.20M $4.975M $3.035M
YoY Change 504.0% -43.07% -80.06%
SHAREHOLDERS EQUITY
Retained Earnings -$203.3M -$178.3M
YoY Change 17.2% 17.23%
Common Stock $12.00K $12.00K
YoY Change 100.0% 500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.30M $119.9M $142.9M
YoY Change
Total Liabilities & Shareholders Equity $98.60M $124.9M $145.9M
YoY Change -21.06% 216.15% 402.02%

Cashflow Statement

Concept 2019 2018 Q4 2018 Q1
OPERATING ACTIVITIES
Net Income -$55.18M -$10.84M -$5.042M
YoY Change 83.59% 88.52% 21.85%
Depreciation, Depletion And Amortization $146.0K $0.00 $33.00K
YoY Change -2.01% -100.0% -31.25%
Cash From Operating Activities -$43.61M -$9.100M -$5.107M
YoY Change 52.74% 44.44% 18.77%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$200.0K $198.0K
YoY Change -126.6% 6500.0%
Acquisitions
YoY Change
Other Investing Activities $27.50M $4.400M $1.000M
YoY Change -138.79% -393.33% -85.29%
Cash From Investing Activities $27.39M $4.200M $803.0K
YoY Change -138.41% -380.0% -88.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $106.8M
YoY Change 5893.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 327.0K 0.000 111.2M
YoY Change -99.71% -100.0% -2324.48%
NET CHANGE
Cash From Operating Activities -43.61M -9.100M -5.107M
Cash From Investing Activities 27.39M 4.200M 803.0K
Cash From Financing Activities 327.0K 0.000 111.2M
Net Change In Cash -15.89M -4.900M 106.9M
YoY Change -238.72% -253.12% -4439.29%
FREE CASH FLOW
Cash From Operating Activities -$43.61M -$9.100M -$5.107M
Capital Expenditures -$100.0K -$200.0K $198.0K
Free Cash Flow -$43.51M -$8.900M -$5.305M
YoY Change 50.41% 41.27% 23.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M24D
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Liabilities
Liabilities
4975000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4279000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2106000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
15000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
483000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
304000
CY2019Q4 us-gaap Assets
Assets
98554000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7031000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28899000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4801000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2043000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1319000
CY2019Q4 us-gaap Liabilities
Liabilities
30218000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12040835
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11954528
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11954528
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12040835
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31213000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
88914000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3814000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
123991000
CY2019Q4 cbio Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
435000
CY2019 us-gaap Profit Loss
ProfitLoss
-55178000
CY2018 us-gaap Profit Loss
ProfitLoss
-30055000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3204000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2606000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
146000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
149000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15000000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
490000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2895000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3031000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
500000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5599000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
850000
CY2019 cbio Increase Decrease In Operating Lease Liability And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
75000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28553000
CY2018 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
127967000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27392000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71321000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31263000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19805000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
76900000
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity File Number
EntityFileNumber
000-51173
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2020050
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Blvd
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 710
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2019 dei City Area Code
CityAreaCode
650
CY2019 dei Local Phone Number
LocalPhoneNumber
871-0761
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15369000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
61496000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15000000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4201000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
96066000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
257000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
543000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1927000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
386000
CY2018Q4 us-gaap Assets
Assets
124920000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1248000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41219
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
182722
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
11395
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1577541
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.85
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.57
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.36
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
96.49
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.85
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
450900
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
68336000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98554000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258520000
CY2019 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
2099000
CY2018 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
3767000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
323279000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203342000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
119945000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124920000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1495000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
15000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
174000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
400000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6000
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
cbio:ContractMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
cbio:ContractMember
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21474000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-57277000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55140000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
30774000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
207000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
30981000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2606000
CY2018 cbio Stock Issued During Period Value Common Stock For Follow On Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockForFollowOnOfferingNetOfIssuanceCosts
106762000
CY2018 cbio Stock Issued During Period From Stock Grants And Stock Options Exercised Value
StockIssuedDuringPeriodFromStockGrantsAndStockOptionsExercisedValue
107000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3204000
CY2019 cbio Stock Issued During Period From Stock Grants And Stock Options Exercised Value
StockIssuedDuringPeriodFromStockGrantsAndStockOptionsExercisedValue
327000
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-116000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
15000000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6000
CY2018 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-182000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43613000
CY2019 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
157433000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
129977000
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
198912000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
376000
CY2018 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
5082000
CY2018 cbio Proceeds From Issuance Of Common Stock For Secondary Public Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockForSecondaryPublicOfferingNetOfIssuanceCosts
106762000
CY2019 cbio Proceeds From Issuance Of Common Stock From Stock Grants And Option Exercises
ProceedsFromIssuanceOfCommonStockFromStockGrantsAndOptionExercises
327000
CY2018 cbio Proceeds From Issuance Of Common Stock From Stock Grants And Option Exercises
ProceedsFromIssuanceOfCommonStockFromStockGrantsAndOptionExercises
107000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9545000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
327000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
111332000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15894000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11458000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15369000
CY2018 cbio Noncash Impact On Adoption Of New Accounting Principle
NoncashImpactOnAdoptionOfNewAccountingPrinciple
207000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3000
CY2019 cbio Non Cash Or Part Non Cash Right Of Use Asset And Operating Lease Liability Recorded Upon Adoption Net
NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet
2052000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="NOTES_TO_CONSOLIDATED"></a><a name="NOTES_TO_CONSOLIDATED"></a>Nature of Operations</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a clinical-stage biopharmaceutical company focused on developing novel treatments for hemophilia and other rare bleeding disorders using its engineered subcutaneous (SQ) coagulation factors that promote blood clotting. The Company is located in South San Francisco, California and operates in<font style="color:#000000;"> one segment.</font> </p>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, convertible notes and related warrants up to the date of conversion, common stock and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts for the year ended December 31, 2018 have been reclassified, to be consistent with the current year's presentation.</p>
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.76
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
158.81
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.04
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
76865000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
119057000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
119053000
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019Q4 cbio Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
4320000
CY2018Q4 cbio Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
1012000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2026000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
597000
CY2018Q4 cbio Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
234000
CY2019Q4 cbio Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
250000
CY2018Q4 cbio Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
200000
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-04-30
CY2019 cbio Lessee Operating Lease Renewal Term Description
LesseeOperatingLeaseRenewalTermDescription
no stated renewal options
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M29D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
578000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
15000000
CY2019 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
0
CY2018 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
50000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
15000000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
76865000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
119053000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
76831000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
34000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
596000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
613000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
209000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1996000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
194000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1802000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
562000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
821741
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
612050
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12716
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
43315
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
15783
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1361977
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
740356
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1014126
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.69
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.13
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.17
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2145000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2229000
CY2018 us-gaap Investment Income Dividend
InvestmentIncomeDividend
4000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1650000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-116000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.30
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M1D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6376000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
213000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2294000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
159000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1350000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3204000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2606000
CY2019 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
24235
CY2018 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
6790
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1577541
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0006
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0003
CY2019 cbio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0043
CY2018 cbio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0068
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.1120
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0076
CY2019 cbio Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
0.0000
CY2018 cbio Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
0.2016
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3120
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3933
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0063
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0194
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
936000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
751000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34392000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23559000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9945000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3772000
CY2019Q4 cbio Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
10000
CY2018Q4 cbio Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
3000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45283000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28085000
CY2019 cbio Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
6100000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1871000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1573000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1475000
CY2018 cbio Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
13000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
85000
CY2019 cbio Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
45000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
253000
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
106800000
CY2018 cbio Milestone Payment Received
MilestonePaymentReceived
1500000
CY2017Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2070000
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.50
CY2017Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
5000000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1751708
CY2018 cbio Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1735419
CY2018 cbio Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
6095
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10194
CY2019 cbio Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
2337
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7857
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.46
CY2018 cbio Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Exercised
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised
5.50
CY2018 cbio Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
5.50
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
155.73
CY2019 cbio Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
499.50
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
53.61
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55178000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30055000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1585398
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1372171

Files In Submission

Name View Source Status
0001564590-20-005546-index-headers.html Edgar Link pending
0001564590-20-005546-index.html Edgar Link pending
0001564590-20-005546.txt Edgar Link pending
0001564590-20-005546-xbrl.zip Edgar Link pending
cbio-10k_20191231.htm Edgar Link pending
cbio-20191231.xml Edgar Link completed
cbio-20191231.xsd Edgar Link pending
cbio-20191231_cal.xml Edgar Link unprocessable
cbio-20191231_def.xml Edgar Link unprocessable
cbio-20191231_lab.xml Edgar Link unprocessable
cbio-20191231_pre.xml Edgar Link unprocessable
cbio-ex1017_708.htm Edgar Link pending
cbio-ex1018_773.htm Edgar Link pending
cbio-ex1020_631.htm Edgar Link pending
cbio-ex231_7.htm Edgar Link pending
cbio-ex311_710.htm Edgar Link pending
cbio-ex321_711.htm Edgar Link pending
cbio-ex41_709.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gshfic5viqos000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending